Concepedia

Van K. Morris

VK

Statistics

Publications

83

Citations

6.7K

H-Index

36

Active since

2013

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Guardant (United States)

Vanderbilt University

Vanderbilt-Ingram Cancer Center

Memorial Sloan Kettering Cancer Center

Van K. Morris is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and radiation oncology.

ORCID

Top concepts

Publications per year

2013–2025

83

Publications

83

Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer

Scott Kopetz, Axel Grothey, Rona Yaeger et al. · New England Journal of Medicine · 2019 · 1.4K citations · Full text

Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer

Scott Kopetz, Jayesh Desai, Emily Chan et al. · Journal of Clinical Oncology · 2015 · 678 citations · Full text

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study

Van K. Morris, Mohamed E. Salem, Halla Nimeiri et al. · The Lancet Oncology · 2017 · 383 citations

, , +4

Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)

Scott Kopetz, Katherine A. Guthrie, Van K. Morris et al. · Journal of Clinical Oncology · 2020 · 381 citations · Full text

Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes

Jonathan M. Loree, Allan Andresson Lima Pereira, Michael Lam et al. · Clinical Cancer Research · 2017 · 310 citations · Full text

1–5 of 83